Trials / Recruiting
RecruitingNCT06656494
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 266 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-248 | Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle |
| DRUG | Azacitidine | Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol，once daily on days 1-7 of each 28-day cycle. |
Timeline
- Start date
- 2024-12-18
- Primary completion
- 2027-06-01
- Completion
- 2028-01-01
- First posted
- 2024-10-24
- Last updated
- 2026-04-13
Locations
18 sites across 3 countries: United States, Australia, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06656494. Inclusion in this directory is not an endorsement.